Panel Discussion: What Do Clinical Trials Really Tell Us?
Sunday, December 4, 2011

Gregory L. Krauss, MD - Moderator
Professor of Neurology
Johns Hopkins University
Baltimore, MD

American Epilepsy Society | Annual Meeting
Panel Members

Gregory L. Krauss, MD
Professor of Neurology
Johns Hopkins University
Baltimore, MD

Elinor Ben-Menachem, MD, PhD
Professor of Neurology and Epilepsy
Institute for Clinical Neurosciences and Physiology
Göteborg University
Göteborg, Sweden

Jacqueline French, MD
Professor, Department of Neurology
NYU, Comprehensive Epilepsy Center
Director of the Clinical Trials Consortium
New York, NY

American Epilepsy Society | Annual Meeting
Disclosures

• **Gregory Krauss, MD** – Direct investigator funding from Vertex Laboratories, Novartis, Eisai Laboratories, Sunovion, UCB Pharma, Neuronex, NIA; Eisai Laboratories for Consulting

• **Elinor Ben-Menachem, MD, PhD** – Indirect funding from Eisai, UCB, GlaxoSmithKlein, Lundbeck for Consulting/Advisory Board; Indirect Research/Funding from Eisai and UCB
Disclosures

- Jacqueline French, MD – Indirect funding from Catalyst (consulting), Cyberonics (consulting), Eisai (advisory board, consulting), Entra Pharmaceuticals (consulting), GlaxoSmithKline (consulting), Icagen (consulting), Jazz Pharmaceuticals (consulting), MAPPharma (consulting), Ono Pharma USA, Inc (consulting), Ovation/Lundbeck (consulting), Pfizer (consulting), Sepracor (consulting, advisory board), Sunovion (consulting, advisory board), SK Life Science (consulting), Supernus Pharmaceuticals (consulting), Taro (consulting), UCB Inc/Schwarz Pharma (consulting, advisory board), Upsher Smith (consulting, advisory board), Vertex (consulting, advisory board). All proceeds go to the Epilepsy Study Consortium; Principle investigator on multicenter trials for UCB, Lundbeck, Supernus.
Panel Discussion:
What Do Clinical Trials Really Tell Us?

American Epilepsy Society | Annual Meeting